Back to Results

Evommune Inc (EVMN)

Featured in Small-Cap Stocks

Evommune, Inc. is a clinical-stage biotechnology company focused on developing therapies for chronic inflammatory diseases in the United States. Its research programs are centered on conditions such as chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company’s pipeline includes EVO756, which is being studied for CSU and AD, and EVO301, which is being developed for AD and UC. Founded in 2020 and based in Palo Alto, California, Evommune trades as common stock on the NYSE under the symbol EVMN.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-EVMN
$12.19
3.1% Upside
Fair
$31.14
163.5% Upside
Bargain
Fair
—
—
—
0.0%
September 2, 2026
-5.6x
1.4x
42.4x
415.3 M
126 M
2.1%
50.2%
12.7
—
105.8%
Send a message
Valuation • Fair Value

Evommune Inc (NYSE-EVMN) Fair Value by Valuation Model

Compare the primary fair value estimate for Evommune Inc (NYSE-EVMN) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$12.19

Estimated upside of 3.1% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

$13.66

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

$12.22

Earnings power value estimate.

Comps Fair Value

$11.69

Comparable-company valuation reference.

Analyst Price Target

$31.14

Analysts imply upside of 163.5%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Evommune Inc (NYSE-EVMN) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Evommune Inc (NYSE-EVMN)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

10 M

Current operating scale indicator.

Revenue Forecast

20.15 M

Forward revenue estimate.

EBITDA

-88.632 M

Current operating profitability reference.

EBITDA Forecast

-108.9 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Evommune Inc (NYSE-EVMN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Evommune Inc (NYSE-EVMN)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

12.7

Relatively strong balance-sheet zone.

FCF / Net Income

105.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Evommune Inc (NYSE-EVMN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Evommune Inc (NYSE-EVMN)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

September 2, 2026

Days to Earnings

43

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Evommune Inc (NYSE-EVMN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Evommune Inc (NYSE-EVMN) Stock Forecast & Technical Outlook

Review Evommune Inc (NYSE-EVMN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Evommune Inc (NYSE-EVMN) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Evommune Inc (NYSE-EVMN) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Evommune Inc (NYSE-EVMN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Evommune Inc (NYSE-EVMN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for Evommune Inc (NYSE-EVMN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Evommune Inc (NYSE-EVMN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Evommune Inc (NYSE-EVMN) has a Strong Buy consensus, with 5 buy, 2 hold and 0 sell recommendations in the current data set.

Buy 5
Hold 2
Sell 0
FAQ • Fast Investor Answers

Evommune Inc (NYSE-EVMN) Stock FAQ

Quick answers about Evommune Inc (NYSE-EVMN) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$12.19
Estimated upside 3.1%
Valuation Rating
Undervalued
Estimated upside of 3.1%
Analyst Target
$31.14
Implied upside 163.5%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Evommune Inc (NYSE-EVMN) is $12.19. This implies an estimated upside of 3.1% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 3.1% versus the current market price.

The available analyst price target for Evommune Inc (NYSE-EVMN) is $31.14. The analyst target implies estimated upside of 163.5%.

The current financial health read for Evommune Inc (NYSE-EVMN) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Evommune Inc (NYSE-EVMN) is September 2, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Evommune Inc (NYSE-EVMN) is -5.6x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Evommune Inc is 415.3 M.

The current enterprise value listed for Evommune Inc is 126 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Evommune Inc is NYSE-EVMN, and the stock is listed on NYSE.

Evommune Inc (NYSE-EVMN) is listed on NYSE.

The current debt-to-total-capital ratio listed for Evommune Inc is 2.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Evommune Inc is 50.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks on NYSE View more

AbbVie Inc (ABBV) AbbVie Inc (ABBV)
Arcus Biosciences Inc (RCUS) Arcus Biosciences Inc (RCUS)
Biohaven Pharmaceutical Holding Co Ltd (BHVN) Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Emergent Biosolutions Inc (EBS) Emergent Biosolutions Inc (EBS)
Perspective Therapeutics Inc (CATX) Perspective Therapeutics Inc (CATX)
Lineage Cell Therapeutics Inc (LCTX) Lineage Cell Therapeutics Inc (LCTX)
Protalix Biotherapeutics Inc (PLX) Protalix Biotherapeutics Inc (PLX)
Armata Pharmaceuticals Inc (ARMP) Armata Pharmaceuticals Inc (ARMP)
Adc Therapeutics SA (ADCT) Adc Therapeutics SA (ADCT)
Pelthos Therapeutics Inc (PTHS) Pelthos Therapeutics Inc (PTHS)
Maia Biotechnology Inc (MAIA) Maia Biotechnology Inc (MAIA)
Annovis Bio Inc (ANVS) Annovis Bio Inc (ANVS)
OS Therapies Inc (OSTX) OS Therapies Inc (OSTX)
NanoViricides Inc (NNVC) NanoViricides Inc (NNVC)
Serina Therapeutics Inc (SER) Serina Therapeutics Inc (SER)
Apimeds Pharma US Ltd (APUS) Apimeds Pharma US Ltd (APUS)
Actinium Pharmaceuticals Inc (ATNM) Actinium Pharmaceuticals Inc (ATNM)
CEL-SCI Corp (CVM) CEL-SCI Corp (CVM)
Theriva Biologics Inc (TOVX) Theriva Biologics Inc (TOVX)
Regentis Biomaterials Ltd (RGNT) Regentis Biomaterials Ltd (RGNT)
Aeon Biopharma Inc (AEON) Aeon Biopharma Inc (AEON)
Can Fite Biopharma Ltd ADR (CANF) Can Fite Biopharma Ltd ADR (CANF)
Kairos Pharma Ltd (KAPA) Kairos Pharma Ltd (KAPA)
AIM ImmunoTech Inc (AIM) AIM ImmunoTech Inc (AIM)